- An Taoiseach, Simon Harris, TD,
and Abbott Chairman and Chief Executive Officer, Robert Ford, attend official opening
- Over 800 to be employed at the diabetes technology
manufacturing site, which is part of a €440 million investment
Abbott is making across two sites in Ireland
- Facility will have the highest production of FreeStyle
Libre® sensors in the world
KILKENNY, Ireland, Nov. 18,
2024 /PRNewswire/ -- Abbott (NYSE: ABT) today marked
the official opening of its state-of-the-art manufacturing facility
in Kilkenny, Ireland with a
ceremony attended by An Taoiseach, Simon
Harris, TD, and Abbott Chairman and Chief Executive Officer,
Robert Ford. The site is a global
manufacturing centre of excellence for Abbott's diabetes care
business and will employ more than 800 people.
The Kilkenny facility is part of a €440 million investment in
Ireland, which includes a
significant expansion of the company's Donegal site, where a
further 200 jobs are being created. The new 30,000-square meter
Kilkenny facility is producing FreeStyle Libre 3 sensors, the
world's smallest1 sensors and latest generation in
Abbott's world-leading2 continuous glucose monitoring
portfolio for people living with diabetes.
Speaking at the event, An Taoiseach, Simon Harris, TD, said, "Abbott, which has been
in Ireland since 1946, is one of
the longest-established global companies and largest employers in
our country. This latest investment is a further vote of confidence
in Ireland as a location for
world-class advanced manufacturing and healthcare businesses. With
the opening of this new site, Ireland is now at the global centre of
diabetes care."
"This is our latest commitment to providing innovative care and
supporting people with diabetes to live healthier lives," said
Robert Ford, Chairman and CEO,
Abbott. "The state-of-the-art facility will have the highest
production of Libre sensors in the world to help meet the growing
global demand for our world-leading2 FreeStyle Libre
portfolio."
Abbott's Kilkenny facility was built with sustainability in
mind. The site is fully electric, powered by six air-to-water heat
pumps, has nearly 600 solar panels on the roof and features tanks
for collecting rainwater to use onsite.
Outside Ireland, Abbott is
expanding its manufacturing capacity across Europe with a further £85 million investment
in its Witney facility in Oxfordshire,
UK.
Abbott's FreeStyle Libre portfolio is the world's
leading2 continuous glucose monitoring system, now
helping more than 6 million people across over 60 countries.
About Abbott
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 114,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com and on LinkedIn, Facebook,
Instagram, X and YouTube.
1. Data on file, Abbott Diabetes Care. Among patient-applied
sensors.
2. Data on file. Abbott Diabetes Care. Based on the number of
patients assigned to each manufacturer.
View original
content:https://www.prnewswire.co.uk/news-releases/abbott-opens-state-of-the-art-global-manufacturing-facility-in-kilkenny-ireland-302307416.html
